Published in Thromb J on January 17, 2015
Remarkable regression of massive deep vein thrombosis in response to intensive oral rivaroxaban treatment. Thromb J (2015) 0.78
Short-Term Anticoagulant Therapy and Thrombus Location Are Independent Risk Factors for Delayed Recanalization of Deep Vein Thrombosis. Med Sci Monit (2016) 0.75
Erratum to: 'Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program'. Thromb J (2016) 0.75
The Successful Prevention of Thromboembolism Using Rivaroxaban in a Patient with Antithrombin Deficiency during the Perioperative Period. Intern Med (2017) 0.75
Novel Anticoagulant Therapy of Venous Thromboembolism: Current Status and Future Directions. Ann Vasc Dis (2017) 0.75
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med (1998) 9.43
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost (2007) 3.67
Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med (2002) 3.51
Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost (2000) 3.21
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med (2014) 2.37
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21
A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med (1997) 1.97
Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J (2011) 1.77
Current venous thromboembolism management and outcomes in Japan. Circ J (2014) 1.62
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev (2010) 1.12
Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism. Thromb J (2013) 1.05
Comparison of perfusion lung scanning and angiography in the estimation of vascular obstruction in acute pulmonary embolism. Eur J Nucl Med (1990) 0.95
The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosis. Thromb Haemost (2002) 0.93
A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost (2004) 0.91
Clot resolution after 3 weeks of anticoagulant treatment for pulmonary embolism: comparison of computed tomography and perfusion scintigraphy. J Thromb Haemost (2013) 0.88
Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators. Circulation (2000) 0.88
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. Ann N Y Acad Sci (2013) 0.86
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood (2015) 1.51
Relation Between Left Atrial Wall Thickness in Patients with Atrial Fibrillation and Intracardiac Electrogram Characteristics and ATP-Provoked Dormant Pulmonary Vein Conduction. J Cardiovasc Electrophysiol (2015) 1.46
Significance of imbalance in the ratio of serum n-3 to n-6 polyunsaturated fatty acids in patients with acute coronary syndrome. Am J Cardiol (2013) 0.86
High-sensitivity cardiac troponin T for earlier diagnosis of acute myocardial infarction in patients with initially negative troponin T test--comparison between cardiac markers. J Cardiol (2013) 0.83
Optimal Force-Time Integral for Pulmonary Vein Isolation According to Anatomical Wall Thickness Under the Ablation Line. J Am Heart Assoc (2016) 0.83
Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy. Thromb J (2014) 0.81
Frequency analysis of atrial fibrillation from the specific ECG leads V7-V9: A lower DF in lead V9 is a marker of potential atrial remodeling. J Cardiol (2015) 0.80
Contribution of apolipoprotein A-I to the reduction in high-sensitivity C-reactive protein levels by different statins: comparative study of pitavastatin and atorvastatin. Heart Vessels (2014) 0.79
Transthoracic echocardiographic backscatter-based assessment of left atrial remodeling involving left atrial and ventricular fibrosis in patients with atrial fibrillation. Int J Cardiol (2014) 0.78
Association of n-3 polyunsaturated fatty acids with soluble thrombomodulin as a marker of endothelial damage: a cross-sectional pilot study. J Cardiol (2014) 0.78
Effect of cryoballoon inflation at the right superior pulmonary vein orifice on phrenic nerve location. Heart Rhythm (2015) 0.78
Relations between contact force, bipolar voltage amplitude, and mapping point distance from the left atrial surfaces of 3D ultrasound- and merged 3D CT-derived images: Implication for atrial fibrillation mapping and ablation. Heart Rhythm (2014) 0.77
Prediction of contrast-induced nephropathy by the serum creatinine level on the day following cardiac catheterization. J Cardiol (2015) 0.77
Clinical value of high duke treadmill score with myocardial perfusion SPECT. J Nucl Cardiol (2015) 0.76
Association of lecithin-cholesterol acyltransferase activity measured as a serum cholesterol esterification rate and low-density lipoprotein heterogeneity with cardiovascular risk: a cross-sectional study. Heart Vessels (2015) 0.76
Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study. Clin Drug Investig (2015) 0.76
Erratum to: 'Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program'. Thromb J (2016) 0.75
Effect of adenosine triphosphate on left atrial electrogram interval and dominant frequency in human atrial fibrillation. J Arrhythm (2015) 0.75
Localized rotors and focal impulse sources within the left atrium in human atrial fibrillation: A phase analysis of contact basket catheter electrograms. J Arrhythm (2016) 0.75
Different characteristics of cardiac biomarkers to decide and predict the culprit lesions in patients with suspicious acute coronary syndrome. Heart Vessels (2015) 0.75
A case of cardiac sarcoidosis presenting with double tachycardia. J Arrhythm (2014) 0.75
A case of giant saphenous vein graft aneurysm followed serially after coronary artery bypass surgery. Open Med (Wars) (2016) 0.75
Detection of ROSC in Patients with Cardiac Arrest During Chest Compression Using NIRS: A Pilot Study. Adv Exp Med Biol (2016) 0.75
Spontaneous Remission in a Case of Giant Cell Myocarditis with Preserved Left Ventricular Ejection Fraction. Am J Case Rep (2015) 0.75
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension. Chest (2016) 0.75
The effects of increasing calcium channel blocker dose vs. adding a diuretic to treatment regimens for patients with uncontrolled hypertension. Hypertens Res (2017) 0.75
Successful surgical treatment of an infrarenal abdominal pseudoaneurysm caused by tuberculosis: report of a case. Surg Today (2005) 0.75
Coronary vessel floating sign and vasospastic angina in a patient with cardiac lymphoma. Int J Cardiol (2014) 0.75
Ventriculoatrial Intervals ≤70 ms in Orthodromic Atrioventricular Reciprocating Tachycardia. Pacing Clin Electrophysiol (2016) 0.75
Depiction of the discrepancy between fatty-acid metabolism and myocardial perfusion in takotsubo cardiomyopathy using dedicated cardiac semiconductor gamma camera. Int J Cardiol (2016) 0.75
Usefulness of synthesized 18-lead electrocardiography in the diagnosis of ST-elevation myocardial infarction: A pilot study. Am J Emerg Med (2016) 0.75
Repeated pacemaker dysfunction in a patient with recurrent Takotsubo cardiomyopathy precipitated by hyponatremia. Int J Cardiol (2013) 0.75
Balloon pin-hole rupture during percutaneous coronary intervention for recurrent, calcified in-stent restenosis: A case report. Catheter Cardiovasc Interv (2017) 0.75
Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol (2017) 0.75
Characterization of real-world patients with low fractional flow reserve immediately after drug-eluting stents implantation. Cardiovasc Interv Ther (2015) 0.75
Association of systemic inflammation with the serum apolipoprotein A-1 level: A cross-sectional pilot study. J Cardiol (2015) 0.75
Rationale and design of J-ACCESS 4: prognostic impact of reducing myocardial ischemia identified using ECG-gated myocardial perfusion SPECT in Japanese patients with coronary artery disease. J Cardiol (2013) 0.75
Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial. J Stroke Cerebrovasc Dis (2013) 0.75
Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF. J Stroke Cerebrovasc Dis (2013) 0.75
Multimodality visualization with 3-dimensional reconstruction of neointimal plaque rupture after bare-metal stent implantation. JACC Cardiovasc Interv (2014) 0.75
The Ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid may be a Residual Risk Marker in Stable Coronary Artery Disease Patients Receiving Treatment with Statin Following EPA Therapy. Am J Cardiovasc Drugs (2017) 0.75
A rare variant of pulmonary vein drainage. HeartRhythm Case Rep (2015) 0.75
General anesthesia improves contact force and reduces gap formation in pulmonary vein isolation: a comparison with conscious sedation. Heart Vessels (2017) 0.75